BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

A UCSF team has keyed in on more than five dozen compounds against nearly as many targets that could be repurposed to target the virus behind COVID-19. Meanwhile, a repurposing screen by Aldeyra could yield...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Extra | Aug 14, 2017
Preclinical News

Papers uncover predictive markers for BET inhibitor responses

A trio of papers published in Nature Medicine today challenge the notion that similar mutations in the same gene can predict the same drug responses across different types of cancer. While two separate teams of...
BC Innovations | Mar 21, 2017
Distillery Therapeutics


INDICATION: Colitis In vitro and mouse studies identified a chlorobenzamide-based inhibitor of bromodomain 1 of BET bromodomain proteins that could help treat colitis. Structure-based design, chemical synthesis and in vitro competitive bromodomain binding assays on...
BC Innovations | Mar 9, 2017
Product R&D

Double your pleasure

SignalRx Pharmaceuticals Inc. has developed an in silico platform for designing small molecule dual inhibitors that is more targeted and efficient than the standard approach of experimentally screening vast chemical libraries to find a molecule...
BC Innovations | Jun 23, 2016
Distillery Therapeutics

Therapeutics: BET bromodomain proteins; bromodomain containing 2 (BRD2); BRD3; BRD4; von Hippel-Lindau tumor suppressor (vHL)

Cancer INDICATION: Prostate cancer Cell culture and mouse studies identified a BET bromodomain protein degrader that could help treat castration-resistant prostate cancer (CRPC). Chemical synthesis and testing in three human CRPC cell lines of small...
BC Week In Review | Jan 18, 2016
Company News

Tensha Therapeutics, Roche deal

Roche will acquire Tensha for $115 million in cash plus up to $420 million in undisclosed clinical and regulatory milestones. Tensha’s TEN-010 , a small molecule bromodomain inhibitor that is selective for the bromodomain and extra-terminal...
BC Extra | Jan 12, 2016
Company News

Roche BETs on Tensha

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Tensha Therapeutics Inc. (Cambridge, Mass.) for $115 million in cash up front. Tensha shareholders are eligible for $420 million in milestones. The pharma will gain Tensha's TEN-010 , a small molecule...
BC Innovations | Oct 8, 2015
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); BET bromodomain proteins

Cancer INDICATION: Acute myelogenous leukemia (AML) Studies in mice and patient samples suggest inhibiting the Wnt/ CTNNB1 pathway could help treat BET bromodomain protein inhibitor-resistant AML. In BET inhibitor-resistant AML cells from patients, expression of...
BC Innovations | Jul 16, 2015
Distillery Therapeutics

Therapeutics: BET bromodomain proteins; bromodomain containing 2 (BRD2); BRD3; BRD4; myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)

Cancer INDICATION: Leukemia In vitro studies suggest a new class of BET bromodomain protein inhibitors could help treat MLL-mutant leukemias. Chemical synthesis and in vitro testing of tricyclic pyridoindole analogs identified a compound that selectively...
Items per page:
1 - 10 of 42